Longeveron Inc.

Longeveron Inc. is a clinical-stage biotechnology company focused on developing cellular therapies for aging-related and life-threatening conditions. The company's investigational product, Lomecel-B, is a cell-based therapy derived from culture-expanded medicinal signaling cells (MSCs) sourced from the bone marrow of young, healthy adult donors. Longeveron is dedicated to advancing regenerative medicine through rigorous clinical trials and scientific research. Their efforts target areas with significant unmet medical needs, including Alzheimer's disease, aging frailty, metabolic syndrome, and other age-related illnesses. By harnessing the potential of cellular therapies, Longeveron aims to improve patient outcomes and enhance the quality of life for individuals affected by these challenging conditions. The company is committed to innovation and the pursuit of breakthroughs in the field of regenerative medicine.